Perform microbiological tests on environmental samples in the field settings poses logistical challenges with respect to the availability of appropriate equipment or the ability to obtain samples in the laboratory in a timely manner. For example, the viability of certain bacteria can decrease considerably between sampling and arrival at the treatment laboratory. We have developed and builds robust, reliable and cost-effective laptop incubators used by 10 independent field teams to perform microbiological tests on Canadian lake surface water samples. Rigorous tests and validation of our incubators have made it possible to coherent the incubation conditions in the fields of land and 2 years of sampling.
The samples of all sites have been treated in duplicate and bacterial accounts were highly repeatable in sampling teams and between sampling teams. Bacterial figures have also been found statistically equivalent to the counts obtained with standard laboratory techniques using a conventional incubator. Using this method, thermotolerant coliforms (TTCs) and Escherichia coli have been quantified from 432 lakes, thus making it possible to compare the two historical data sets on the TCTs and those following current directives that use accounts E. coli. We found higher shore loads than the mid-lakes and different patterns between ecozones. E. coli has not been often detected, but many lakes have exceeded Canadian guidelines for activities such as swimming and some have even exceeded the value of the directive of secondary leisure activities such as boating.
To our knowledge, this is the largest assessment of bacteriological water quality of freshwater lakes to date in terms of spatial ladder and number of lakes sampled. Our incubator design can be easily adapted to a wide variety of researcher goals and represents a robust platform for field studies and other applications, including remote or low-resource settings.
The investigation into the suction culture of pediatric endotracheal aspiration (PETACS): examining the variation of practice in pediatric microbiology laboratories in the United States
Introduction: In the absence of evidence-based laboratory guidelines, the work and interpretation of tracheal aspiration crops (TA) remains controversial and confusing in the areas of clinical microbiology, infectious diseases and critical care. Methods: Between January 22nd and February 24, 2020, we conducted a national web survey on microbiology laboratory personnel in autonomous pediatric hospitals and adult hospitals containing pediatric facilities for laboratory practices used for laboratory practices used for Specimens Ta. We hypothesized that there would be a substantial central variability in Ta.Results crop laboratory processes: the survey response rate was 48% (73/153). There was a high level of variability in the criteria used for all processes, including the reception of the samples, the coloring of grams and the culture ratios.
Most respondents (77%) reported that they do not join TA-based samples based on grams stain criteria and 44% of laboratories do not require a minimum number of grams task fields are examined before reporting. the results. Overall, non-academic hospital laboratories and pediatric laboratories are no longer likely to identify, report and test susceptibility on state cultural organizations, regardless of the amount of organism or The predominance. Conclusion: There is a substantial amount of process variability in pediatric microbiology laboratories that affects reports on TA culture, which guides treatment decisions. This variation within and between laboratories renders clinical outcome studies related to HAS cultures difficult to interpret. This study is a pragmatic step to inform the development of robust clinical guidelines. Clinical studies and implementation studies are needed to determine the effectiveness of TA crop guidelines.
Microbiology in the Field: Construction and Validation of a Portable Incubator for Real-Time Quantification of Coliforms and Other Bacteria
Autonomous and assisted control for synthetic microbiology
Control of microbial microbes and consortia for specific functions requires synthetic circuits that can be reliably facing internal and external disturbances. The circuits that have naturally evolved to regulate the biological functions are often robust for changes in their parameters. As the complexity of synthetic circuits increases, synthetic biologists must implement such a robust control “by design”. This is especially true for intercellular signaling circuits for synthetic consortia, where robustness is highly desirable, but its mechanisms remain uncertain. Cybergenetics, the interface between synthetic biology and the control theory, offers two approaches to this challenge: external control (computer-assisted) and internal (autonomous).
Here we examine natural and synthetic microbial systems with robustness and describe experimental approaches to implement such a strong control in microbial consortia through cyber genetic at the level of the population. We propose that the exploitation of natural topologies between intercellular circuits with robust evolving functions can help obtain a robust control similar in synthetic intercellular circuits. A “hybrid biology” approach, where robust synthetic microbes interact with natural consortia and, with external computers, could become a useful tool for health and environmental applications. Microbiota (FMT) transplantation is an effective and safe treatment of difficult recurring clostriadies. infection.
Description: Quantitative sandwich ELISA for measuring Rat Protein Tob1 (TOB1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Rat Protein Tob1 (TOB1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Rat Protein Tob1 (TOB1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Protein Tob2 (TOB2) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Protein Tob2 (TOB2) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Protein Tob2 (TOB2) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Protein Tob1 (TOB1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Protein Tob1 (TOB1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Protein Tob1 (TOB1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Mouse Protein Tob2 (TOB2) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Mouse Protein Tob2 (TOB2) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Mouse Protein Tob2 (TOB2) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Mouse Protein Tob1 (TOB1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Mouse Protein Tob1 (TOB1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Mouse Protein Tob1 (TOB1) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Enzyme-linked immunosorbent assay kit for quantification of Biotin in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Enzyme-linked immunosorbent assay kit for quantification of General Biopterin in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Enzyme-linked immunosorbent assay kit for quantification of Bovine Biotinidase, Biotinase in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: A sandwich ELISA kit for detection of Biotinidase from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is unconjugated.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 390.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 488.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 594.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to APC .
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Biotin.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to FITC.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to HRP.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to PerCP.
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to RPE .
Description: A polyclonal antibody for CD9 from Human | Mouse | Rat. The antibody is produced in rabbit after immunization with A synthesized peptide. The Antibody is tested and validated for WB, IHC, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:200), ICC/IF (1:200). This CD9 antibody is conjugated to Streptavidin.
×
It is essential to make every effort to perform FMT rigorously and based on scientific knowledge. The selection of the Fecal Microbiota Donor is a key part of the process to ensure the security of recipients. Protocols of action must be implemented that allow clinicians to act with maximum guarantees and minimize the risk of procedural. In this regard, a multidisciplinary working group has been put in place to make recommendations to select the Fecal Microbiota donor.
Gina
